<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2695-463X</journal-id>
<journal-title><![CDATA[Revista Española de Podología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Esp Podol.]]></abbrev-journal-title>
<issn>2695-463X</issn>
<publisher>
<publisher-name><![CDATA[Inspira Network Group, S.L]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2695-463X2025000200148</article-id>
<article-id pub-id-type="doi">10.20986/revesppod.2025.1740/2025</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Revisión sistemática de la afectación podológica en el síndrome de andrade]]></article-title>
<article-title xml:lang="en"><![CDATA[Systematic review of podiatric involvement in andrade syndrome]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Alfageme García]]></surname>
<given-names><![CDATA[María del Pilar]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Basilio Fernández]]></surname>
<given-names><![CDATA[Belinda]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martí Antonio]]></surname>
<given-names><![CDATA[Manuel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gómez Luque]]></surname>
<given-names><![CDATA[Adela]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Torres Pére]]></surname>
<given-names><![CDATA[Alba]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hidalgo Ruiz]]></surname>
<given-names><![CDATA[Sonia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Extremadura Centro Universitario de Plasencia ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad de Extremadura Departamento de Matemáticas ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad de Extremadura Centro Universitario de Cáceres ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Spain</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2025</year>
</pub-date>
<volume>36</volume>
<numero>2</numero>
<fpage>148</fpage>
<lpage>155</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S2695-463X2025000200148&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S2695-463X2025000200148&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S2695-463X2025000200148&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción:  El síndrome de Andrade, o polineuropatía amiloidótica familiar tipo I, es un trastorno genético raro causado por mutaciones en el gen de la transtiretina. Estas mutaciones provocan depósitos amiloides en los nervios periféricos y otros tejidos. Los pies se encuentran entre las regiones más afectadas, provocando pérdida sensorial, lesiones no reconocidas, infecciones y deformidades como el pie de Charcot. El presente trabajo realiza una revisión sistemática para determinar las complicaciones del pie en pacientes con síndrome de Andrade.  Material y métodos:  Se realizó una revisión sistemática de acuerdo con las directrices PRISMA 2020. Se realizaron búsquedas en PubMed, Web of Science y Google Scholar hasta diciembre de 2024. Se incluyeron 13 estudios publicados entre 2019 y 2024. El riesgo de sesgo se evaluó mediante las herramientas ROBINS-I y RoB 2.  Resultados:  Las complicaciones del pie en pacientes con síndrome de Andrade incluyeron úlceras, infecciones, deformidades estructurales, dolor neuropático y pie de Charcot. Estas afecciones se asociaron a una reducción de la movilidad, un aumento del riesgo de caídas y una disminución de la calidad de vida. Las estrategias terapéuticas incluían fisioterapia, ortesis, calzado especializado y tratamiento farmacológico precoz con tafamidis o patisirán.  Conclusión:  Las complicaciones relacionadas con los pies son frecuentes en los pacientes con síndrome de Andrade y merman significativamente su independencia funcional y su bienestar. La detección precoz y la atención multidisciplinar son esenciales para mejorar los resultados clínicos y preservar la calidad de vida.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction:  Andrade syndrome, or familial amyloid polyneuropathy type I, is a rare genetic disorder caused by mutations in the transthyretin gene. These mutations lead to amyloid deposits in peripheral nerves and other tissues. The feet are among the most affected regions, resulting in sensory loss, unrecognized injuries, infections, and deformities such as Charcot foot. This paper makes a systematic review of the frequency of foot complications in patients with Andrade syndrome.  Materials and methods:  A systematic review was conducted in accordance with PRISMA 2020 guidelines. Searches were performed in PubMed, Web of Science, and Google Scholar up to December 2024. Thirteen studies published between 2019 and 2024 were included. Risk of bias was assessed using ROBINS-I and RoB 2 tools.  Results:  Foot complications in patients with Andrade syndrome included ulcers, infections, structural deformities, neuropathic pain, and Charcot foot. These conditions were associated with reduced mobility, increased risk of falls, and decreased quality of life. Therapeutic strategies included physiotherapy, orthoses, specialized footwear, and early pharmacological treatment with tafamidis or patisirán.  Conclusion:  Foot-related complications are common in patients with Andrade syndrome and significantly impair their functional independence and well-being. Early detection and multidisciplinary care are essential to improve clinical outcomes and preserve quality of life.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Amiloidosis]]></kwd>
<kwd lng="es"><![CDATA[polineuropatía]]></kwd>
<kwd lng="es"><![CDATA[lesiones del pie]]></kwd>
<kwd lng="es"><![CDATA[calidad de vida]]></kwd>
<kwd lng="en"><![CDATA[Amyloidosis]]></kwd>
<kwd lng="en"><![CDATA[polyneuropathy]]></kwd>
<kwd lng="en"><![CDATA[foot injuries]]></kwd>
<kwd lng="en"><![CDATA[quality of life.]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Murakami]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Yokoyama]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Mizuguchi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Toné]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Takaku]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sango]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A low amyloidogenic E61K transthyretin mutation may cause familial amyloid polyneuropathy]]></article-title>
<source><![CDATA[J Neurochem]]></source>
<year>2021</year>
<volume>156</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>957-66</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Luigetti]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Romano]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[di Paolantonio]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bisogni]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Sabatelli]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnosis and treatment of hereditary transthyretin amyloidosis (hATTR) polyneuropathy: Current perspectives on improving patient care]]></article-title>
<source><![CDATA[Ther Clin Risk Manag]]></source>
<year>2020</year>
<volume>16</volume>
<page-range>109-23</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Adams]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Ando]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Beirão]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Coelho]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Gertz]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Gillmore]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy]]></article-title>
<source><![CDATA[J Neurol]]></source>
<year>2021</year>
<volume>268</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>2109-22</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kucera]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Shaikh]]></surname>
<given-names><![CDATA[HH]]></given-names>
</name>
<name>
<surname><![CDATA[Sponer]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Charcot neuropathic arthropathy of the foot: A literature review and single-center experience]]></article-title>
<source><![CDATA[J Diabetes Res]]></source>
<year>2016</year>
<volume>2016</volume>
<page-range>3207043</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Seixas]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Vilas-Boas]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Carvalho]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Coelho]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Ammer K Vilas-Boas]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Skin temperature of the foot: Comparing transthyretin familial amyloid polyneuropathy and diabetic foot patients]]></article-title>
<source><![CDATA[Comput Methods Biomech Biomed Eng Imaging Vis]]></source>
<year>2019</year>
<volume>7</volume>
<numero>5-6</numero>
<issue>5-6</issue>
<page-range>504-11</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tozza]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Luigetti]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Antonini]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Mazzeo A Severi]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[di Paolantonio]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neuropathic pain experience in symptomatic and presymptomatic subject carrying a transthyretin gene mutations]]></article-title>
<source><![CDATA[Front Neurol]]></source>
<year>2023</year>
<volume>14</volume>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Girach]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Julian]]></surname>
<given-names><![CDATA[TH]]></given-names>
</name>
<name>
<surname><![CDATA[Varrassi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Paladini]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Vadalouka]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Zis]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Quality of life in painful peripheral neuropathies: A systematic review]]></article-title>
<source><![CDATA[Pain Res Manag]]></source>
<year>2019</year>
<volume>2019</volume>
<page-range>2091960</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Coelho]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Maia]]></surname>
<given-names><![CDATA[LF]]></given-names>
</name>
<name>
<surname><![CDATA[Martins da Silva]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cruz]]></surname>
<given-names><![CDATA[MW]]></given-names>
</name>
<name>
<surname><![CDATA[Palnté-Bordeneuve]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Suhr]]></surname>
<given-names><![CDATA[OB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term effects of tafamidis for the treatmen of transthyretin familial amyloid polyneuropathy]]></article-title>
<source><![CDATA[J Neurol]]></source>
<year>2013</year>
<volume>260</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>2802-14</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ziegler]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Burow]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Landgraf]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Lobmann]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Reiners]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Rett]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Current practice of podiatrists in testing for diabetic polyneuropathy and implementing foot care (PROTECT Study Survey 2)]]></article-title>
<source><![CDATA[Endocr Pract]]></source>
<year>2024</year>
<volume>30</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>817-21</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moher]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Liberati]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Tetzlaff]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Altman]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement]]></article-title>
<collab>PRISMA Group</collab>
<source><![CDATA[PLoS Med]]></source>
<year>2009</year>
<volume>6</volume>
<numero>7</numero>
<issue>7</issue>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Page]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[McKenzie]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Bossuyt]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Boutron]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Hoffmann]]></surname>
<given-names><![CDATA[TC]]></given-names>
</name>
<name>
<surname><![CDATA[Mulrow]]></surname>
<given-names><![CDATA[CD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The PRISMA 2020 statement: An updated guideline for reporting systematic reviews]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>2021</year>
<volume>372</volume>
<page-range>n71</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Coelho]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Waddington Cruz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Chao]]></surname>
<given-names><![CDATA[CC]]></given-names>
</name>
<name>
<surname><![CDATA[Parman]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Wixner]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Weiler]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Characteristics of patients with hereditary transthyretin amyloidosis-polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an open-label phase 3 study of eplontersen]]></article-title>
<source><![CDATA[Neurol Ther]]></source>
<year>2023</year>
<volume>12</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>267-87</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Karam]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Mauermann]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Gonzalez-Duarte]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kaku]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Ajroud-Driss]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Brannagan]]></surname>
<given-names><![CDATA[TH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnosis and treatment of hereditary transthyretin amyloidosis with polyneuropathy in the United States: Recommendations from a panel of experts]]></article-title>
<source><![CDATA[Muscle Nerve]]></source>
<year>2024</year>
<volume>69</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>273-87</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leonardi]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Adam]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Beaudonnet]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Beauvais]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Cauquil]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Not]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Skin amyloid deposits and nerve fiber loss as markers of neuropathy onset and progression in hereditary transthyretin amyloidosis]]></article-title>
<source><![CDATA[Eur J Neurol]]></source>
<year>2022</year>
<volume>29</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1477-87</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Silva-Hernández]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Horga Hernández]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Valls Carbó]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Guerrero Sola]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Montalvo-Moraleda]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Galán Dávila]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Red flags in patients with hereditary transthyretin amyloidosis at diagnosis in a non-endemic area of Spain]]></article-title>
<source><![CDATA[Neurology (Eng Ed)]]></source>
<year>2023</year>
<volume>38</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>87-92</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cárdenas-Soto]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Dominguez]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Cortes]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Tsai]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Saniger]]></surname>
<given-names><![CDATA[MDM]]></given-names>
</name>
<name>
<surname><![CDATA[Guraieb-Chahin]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cutaneous biomarkers of therapeutic efficacy in early treatment of hereditary ATTR amyloid polyneuropathy with tafamidis]]></article-title>
<source><![CDATA[J Peripheral Nervous Sys]]></source>
<year>2024</year>
<volume>29</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>221-31</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Escolano-Lozano]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Geber]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Barreiros]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
<name>
<surname><![CDATA[Birklein]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Follow-up in transthyretin familial amyloid polyneuropathy: Useful investigations]]></article-title>
<source><![CDATA[J Neurol Sci]]></source>
<year>2020</year>
<volume>413</volume>
<page-range>116776</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bolte]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Langenstroer]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Friebel]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Hüsing-Kabar]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Dugas]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Schmidt]]></surname>
<given-names><![CDATA[HH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Patient-reported outcomes on familial amyloid polyneuropathy (FAP)]]></article-title>
<source><![CDATA[Orphanet J Rare Dis]]></source>
<year>2020</year>
<volume>15</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>287</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lepesis]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Paton]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Rickard]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Latour]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Marsden]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of foot and ankle mobilisations combined with home stretches in people with diabetic peripheral neuropathy: A proof-of-concept RCT]]></article-title>
<source><![CDATA[J Foot Ankle Res]]></source>
<year>2023</year>
<volume>16</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>88</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tseng]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Chan]]></surname>
<given-names><![CDATA[WP]]></given-names>
</name>
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Natural history and survival rate of familial amyloidosis with polyneuropathy: A nationwide databank]]></article-title>
<source><![CDATA[Ann Clin Transl Neurol]]></source>
<year>2023</year>
<volume>10</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>779-86</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Coelho]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Adams]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Conceição]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Waddington-Cruz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Schmidt]]></surname>
<given-names><![CDATA[HH]]></given-names>
</name>
<name>
<surname><![CDATA[Buades]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A phase II, open-label, extension study of long-term patisirán treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis]]></article-title>
<source><![CDATA[Orphanet J Rare Dis]]></source>
<year>2020</year>
<volume>15</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>179</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
